DOCSLIB.ORG

The Role of Inguinal Lymph Node Dissection in Men with Urethral Squamous Cell Carcinoma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Role of Inguinal Lymph Node Dissection in Men with Urethral Squamous Cell Carcinoma Urologic Oncology: Seminars and Original Investigations 36 (2018) 526.e1−526.e6 Original Article The role of inguinal lymph node dissection in men with urethral squamous cell carcinoma RyanD1XX P. Werntz, M.D.D2XX*, ChristopherD3XX B. Riedinger,D4RichardD5XXXX J. Fantus,D6ZacharyD7XXXX L. Smith,D8XX VigneshD9XX T. Packiam,D10MelanieD11XXXX A. Adamsky,D12NormD13XXXX Smith,D14GaryD15XX D.XX SteinbergD16XX Department of Surgery, Section of Urology, The University of Chicago, Chicago, IL Received 19 April 2018; received in revised form 7 August 2018; accepted 21 September 2018 Abstract Introduction: Urethral squamous cell cancer is a rare disease with limited clinical recommendations regarding management of the inguinal lymph nodes. Despite the similarities to penile cancer in terms of squamous cell carcinoma (SCC) histology and lymphatic drain- age, there is not enough evidence to recommend for or against a prophylactic inguinal lymph node dissection (ILND) in patients with clini- cally negative groins and a primary tumor stage of T1b or higher. The objective of the study was to identify the rate of prophylactic inguinal lymph node dissection, node positive rate, and overall survival in patients with clinical T1 to T4 stage. The patients were separated into clinical N stage and the rates of node positivity were compared. We hypothesize that the node positivity rate would be similar to that observed in penile cancer of similar clinical T and N stage and provide evidence for prophylactic inguinal lymph node dissection in urethral squamous cancer. We also sought to determine the value of ILND in clinically node positive (cN+) and clinically node negative (cN¡) patients. Methods: The National Cancer Database was queried for all cases of primary urethral cancer in men from 2004 to 2014. Patients with other cancer diagnoses, metastasis, nonsquamous histology, female patients, and patients with a history of radiation therapy were excluded. Male patients with urethral squamous cell cancer of the anterior urethra with T1 or higher T stage were included in this study. All-cause mortality was compared using multivariable Cox regression controlling for covariates. Results: The study included 725 men with urethral SCC with T1 or higher clinical T stage. The median age was 63 years (33−83 inter- quartile range). Of the 725 men, 536 men did not receive an ILND and 189 (26%) underwent ILND. Patients who received LND had signif- icantly higher clinical T and clinical N stage. There was no difference in age, sex, or histology between those with ILND versus no ILND. In patients with T1 to T4 and clinical N0, the ILND rate was 21.8% (89/396). The lymph node positive rate in patients with N0 and T1 to T4 primary tumor was 9%. In patients with clinically node positive disease (N1/N2), the overall ILND rate was 76%. The lymph node posi- tive rate for patients with clinical nodal disease was 84%. On multivariable analysis cox regression, lymph node positivity was associated with worse overall survival when controlling for T stage, clinical N stage, and age (HR 1.56, 95% 1.3−1.9, P = 0.000). On multivariable analysis after controlling for T stage, sex, and age, having an ILND was associated with improved OS in patients with clinical N1 or N2 dis- ease (HR 0.46, 95% 0.28−0.78 P = 0.002). Conclusion: The node positivity rate in patients with T1 to T4 and N0 is 9%, much lower than reported in penile cancer with a high-risk primary tumor but clinically negative groins. This argues against routine prophylactic inguinal ILND in patients with urethral SCC who are clinically N0, perhaps suggesting different biological behavior of urethral SCC compared to penile SCC. Performing a lymph node dissec- tion in patients with clinically N1 or N2 disease is associated with improved OS. Published by Elsevier Inc. Keywords: Squamous cell carcinoma; Urethra; Inguinal lymph node dissection Disclosures: none. *Corresponding author. Tel.: 574-855-8741. E-mail address: [email protected] (R.P. Werntz). https://doi.org/10.1016/j.urolonc.2018.09.014 1078-1439/Published by Elsevier Inc. R.P. Werntz et al. / Urologic Oncology: Seminars and Original Investigations 36 (2018) 526.e1−526.e6 526.e2 1. Introduction 2.2. Study population Primary urethral carcinoma (PUC) is a rare clinical We analyzed the NCDB participant user files from 2004 entity and accounts for less than 1% of all genitourinary to 2014. During the study period, 725 male patients were malignancies [1]. This has led to a relative paucity of data diagnosed with primary urethral SCC cancer and met the where management is largely informed by small, single- below inclusion criteria (Fig. 1). Patients with other cancer institution studies. Data from several national and interna- diagnoses, female gender, nonurethral primary, non-SCC tional cohorts have been published [1−4], but important histology, history of radiation of chemotherapy (NCDB questions remain with regard to the optimal management of variables RX_SUMM_SURGRAD_SEQ and this condition. RX_SUMM_CHEMO), and metastatic disease at presenta- The optimal management of lymph nodes for PUC tion were excluded from analysis (Fig. 1). For penile cancer remains unclear. In men, lymphatics from the anterior comparative purposes, only male patients with urethral urethra and penis preferentially drain into the superficial SCC of the anterior urethra with clinical stage ≥ T1 were anddeepinguinallymphnodes[5].PUCoftheanterior included for analysis. Patients were included if they urethra presents with inguinal lymphadenopathy 18% to received ILND within 6 months of diagnosis to remove the 30% of the time; [2,3,6,7] 75% to 100% of these repre- possibility of patients being included who had salvage sent true metastatic disease [8−10]. Pathologic lymph ILND. Clinically node positive disease was defined accord- node involvement has been shown to adversely predict ing to the TNM staging system, as defined by the NCDB survival [2,6] and a benefit for inguinal lymph node dis- variable TNM_CLIN_N. Of the 725 patients, 189 under- section (ILND) has been shown when clinical or radio- went a bilateral ILND. Lymphovascular invasion data was graphic evidence of lymphadenopathy is present [9,11]. missing on most patients was not evaluated as part of this However, there is no current data to argue for or against study. This comprised the patients selected for analysis. prophylactic ILND for PUC. In penile cancer, with seemingly the same lymphatic drainage and histology, 2.3. Statistical analyses prophylactic ILND is supported in patients with high- risk primary disease (T1b or greater) [12]. Patients with cT1-4 primary lesions were separated into We hypothesize that the node positivity rate would be an ILND groups versus an observation group after surgery similar to that observed in penilecancerofsimilarclini- on the primary tumor. These patients were then stratified cal T and N stage and provide evidence for prophylactic according to their clinical N stage and descriptive analyses inguinal lymph node dissection in urethral squamous of the groups were performed using Pearson’s chi-squared cancer. We also sought to determine the value of ILND or Fisher’s exact tests for categorical variables and in clinically node positive (cN+) and clinically node Student’s t-test for continuous variables. We performed negative (cN¡) patients. To examine this issue further, propensity core weighted analysis to assess the effect of we performed a comparative effectiveness analysis using ILND on overall survival. The propensity score was deter- a large, contemporary US hospital-based cancer registry mined by logistic regression. We then ran a Cox regression to better understand outcomes associated with this was used to identify if the performance of a ILND procedure. improved OS in patients with who were cN0 and cN+ after adjusting for covariates (age, cT stage, cN status, Charlson comorbidity index). Multivariable Cox regression was used 2. Methods to identify predictors of overall survival after adjusting for 2.1. Data source cN and cT stage, age, cT stage, pN stage, Charlson comor- bidity index as covariates. All hypotheses testing was two- The National Cancer Data Base (NCDB) is a joint effort sided and a P-value of < 0.05 was considered statistically between the American Cancer Society and the American significant. All statistical analyses were performed using College of Surgeons’ Commission on Cancer (CoC). By Stata, version 13.1 (StataCorp, College Station, TX). collecting data from more than 1,500 CoC-accredited can- cer centers, it is able to capture 70% of all incident malig- 3. Results nancies in the United States. Institutional data is collected using standardized definitions in accordance with the CoC’s Seven hundred twenty five men met inclusion criteria. Facility Oncology Registry Data Standards. All demo- Median age was 63 years (IQR 33−83). Patients with a graphic and clinical patient characteristics are recorded, lower Charlson comorbidity index and higher clinical stage including, but not limited to: cancer staging, pathological were more likely to receive an ILND (Table 1). Of the 725 information, details of first-line treatment administered, men, only 189 (26%) underwent ILND. Patients who under- survival outcomes, hospital length of stay, and readmission went ILND were of significantly higher cT and cN stage. In information. Data quality undergoes routine appraisal to patients with cN0, the ILND rate was 21.8%, with 9% pN+. ensure reliability and quality. In patients with cN1-2, the ILND rate was 76%, with 84% 526.e3 R.P. Werntz et al. / Urologic Oncology: Seminars and Original Investigations 36 (2018) 526.e1−526.e6 Fig. 1. Men with urethral SCC exclusion criteria diagram. SCC = squamous cell carcinoma. pN+. On multivariable Cox regression, pN+ was associated positive and pathologically node positive patients, we eval- with worse overall survival when controlling for cT stage, uated the dropout rate in each group to address the issue of cN stage, Charlson comorbidity, age, and sex (HR 1.56, selection bias (Fig.
Load more

Recommended publications
  • The Male Reproductive System
    Management of Men’s Reproductive 3 Health Problems Men’s Reproductive Health Curriculum Management of Men’s Reproductive 3 Health Problems © 2003 EngenderHealth. All rights reserved. 440 Ninth Avenue New York, NY 10001 U.S.A. Telephone: 212-561-8000 Fax: 212-561-8067 e-mail: [email protected] www.engenderhealth.org This publication was made possible, in part, through support provided by the Office of Population, U.S. Agency for International Development (USAID), under the terms of cooperative agreement HRN-A-00-98-00042-00. The opinions expressed herein are those of the publisher and do not necessarily reflect the views of USAID. Cover design: Virginia Taddoni ISBN 1-885063-45-8 Printed in the United States of America. Printed on recycled paper. Library of Congress Cataloging-in-Publication Data Men’s reproductive health curriculum : management of men’s reproductive health problems. p. ; cm. Companion v. to: Introduction to men’s reproductive health services, and: Counseling and communicating with men. Includes bibliographical references. ISBN 1-885063-45-8 1. Andrology. 2. Human reproduction. 3. Generative organs, Male--Diseases--Treatment. I. EngenderHealth (Firm) II. Counseling and communicating with men. III. Title: Introduction to men’s reproductive health services. [DNLM: 1. Genital Diseases, Male. 2. Physical Examination--methods. 3. Reproductive Health Services. WJ 700 M5483 2003] QP253.M465 2003 616.6’5--dc22 2003063056 Contents Acknowledgments v Introduction vii 1 Disorders of the Male Reproductive System 1.1 The Male
    [Show full text]
  • Genital Ulcers and Swelling in an Adolescent Girl
    PHOTO CHALLENGE Genital Ulcers and Swelling in an Adolescent Girl Meghan E. Ryan, DO; Pui-Ying Iroh Tam, MD A 14-year-old previously healthy, postmenarcheal adolescent girl with a family history of thyroid dis- ease and rheumatoid arthritis presented with vulvar pain and swelling. Vulvar pruritus was noted 6 days prior, which worsened and became associated with vulvar swelling, yellow vaginal discharge, dif- ficulty walking, and a fever (temperature, 39.3°C). Her condition did not improve after a course of cephalexin andcopy trimethoprim-sulfamethoxazole. She denied being sexually active or exposing for- eign objects or chemicals to the vaginal area. not WHAT’S THE DIAGNOSIS? a. Behçet disease Dob. candida c. chlamydia d. Epstein-Barr virus e. herpes simplex virus PLEASE TURN TO PAGE E5 FOR THE DIAGNOSIS CUTIS Dr. Ryan was from Des Moines University College of Osteopathic Medicine, Iowa. Dr. Ryan currently is from and Dr. Iroh Tam is from the University of Minnesota Masonic Children’s Hospital, Minneapolis. Dr. Iroh Tam is from the Department of Pediatric Infectious Diseases and Immunology. The authors report no conflict of interest. Correspondence: Pui-Ying Iroh Tam, MD, 3-210 MTRF, 2001 6th St SE, Minneapolis, MN 55455 ([email protected]). E4 I CUTIS® WWW.CUTIS.COM Copyright Cutis 2017. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher. PHOTO CHALLENGE DISCUSSION THE DIAGNOSIS: Epstein-Barr Virus hysical examination revealed bilateral 1-cm ulcer- is the assumed etiology of genital ulcers, especially in ated lesions on the labia minora with vulvar edema sexually active patients, and misdiagnosis in the setting of P(Figure).
    [Show full text]
  • Corpora Amylacea Act As Containers That Remove Waste Products from the Brain
    Corpora amylacea act as containers that remove waste products from the brain Marta Ribaa,b,c,1, Elisabet Augéa,b,c,1, Joan Campo-Sabariza,d, David Moral-Antera,d, Laura Molina-Porcele, Teresa Ximelise, Ruth Ferrera,d, Raquel Martín-Venegasa,d, Carme Pelegría,b,c,2, and Jordi Vilaplanaa,b,c,2 aSecció de Fisiologia, Departament de Bioquímica i Fisiologia, Universitat de Barcelona, 08028 Barcelona, Spain; bInstitut de Neurociències, Universitat de Barcelona, 08035 Barcelona, Spain; cCentros de Biomedicina en Red de Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain; dInstitut de Recerca en Nutrició i Seguretat Alimentàries (INSA-UB), Universitat de Barcelona, 08291 Barcelona, Spain; and eNeurological Tissue Bank of the Biobanc- Hospital Clinic-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain Edited by Lawrence Steinman, Stanford University School of Medicine, Stanford, CA, and approved November 5, 2019 (received for review August 8, 2019) Corpora amylacea (CA) in the human brain are granular bodies 6). Nonetheless, we observed that CA contain glycogen synthase formed by polyglucosan aggregates that amass waste products of (GS), an indispensable enzyme for polyglucosan formation, and different origins. They are generated by astrocytes, mainly during also ubiquitin and protein p62, both associated with processes of aging and neurodegenerative conditions, and are located predom- elimination of waste substances (5). The relationship between CA inantly in periventricular and subpial regions. This study shows that and waste substances is recurrent in the literature. Already in 1999, CA are released from these regions to the cerebrospinal fluid and after a detailed and complete review, Cavanagh indicated that “CA are present in the cervical lymph nodes, into which cerebrospinal functions seem to be directed towards trapping and sequestration fluid drains through the meningeal lymphatic system.
    [Show full text]
  • Microlymphatic Surgery for the Treatment of Iatrogenic Lymphedema
    Microlymphatic Surgery for the Treatment of Iatrogenic Lymphedema Corinne Becker, MDa, Julie V. Vasile, MDb,*, Joshua L. Levine, MDb, Bernardo N. Batista, MDa, Rebecca M. Studinger, MDb, Constance M. Chen, MDb, Marc Riquet, MDc KEYWORDS Lymphedema Treatment Autologous lymph node transplantation (ALNT) Microsurgical vascularized lymph node transfer Iatrogenic Secondary Brachial plexus neuropathy Infection KEY POINTS Autologous lymph node transplant or microsurgical vascularized lymph node transfer (ALNT) is a surgical treatment option for lymphedema, which brings vascularized, VEGF-C producing tissue into the previously operated field to promote lymphangiogenesis and bridge the distal obstructed lymphatic system with the proximal lymphatic system. Additionally, lymph nodes with important immunologic function are brought into the fibrotic and damaged tissue. ALNT can cure lymphedema, reduce the risk of infection and cellulitis, and improve brachial plexus neuropathies. ALNT can also be combined with breast reconstruction flaps to be an elegant treatment for a breast cancer patient. OVERVIEW: NATURE OF THE PROBLEM Clinically, patients develop firm subcutaneous tissue, progressing to overgrowth and fibrosis. Lymphedema is a result of disruption to the Lymphedema is a common chronic and progres- lymphatic transport system, leading to accumula- sive condition that can occur after cancer treat- tion of protein-rich lymph fluid in the interstitial ment. The reported incidence of lymphedema space. The accumulation of edematous fluid mani- varies because of varying methods of assess- fests as soft and pitting edema seen in early ment,1–3 the long follow-up required for diagnosing lymphedema. Progression to nonpitting and irre- lymphedema, and the lack of patient education versible enlargement of the extremity is thought regarding lymphedema.4 In one 20-year follow-up to be the result of 2 mechanisms: of patients with breast cancer treated with mastec- 1.
    [Show full text]
  • Adaptive Immune Systems
    Immunology 101 (for the Non-Immunologist) Abhinav Deol, MD Assistant Professor of Oncology Wayne State University/ Karmanos Cancer Institute, Detroit MI Presentation originally prepared and presented by Stephen Shiao MD, PhD Department of Radiation Oncology Cedars-Sinai Medical Center Disclosures Bristol-Myers Squibb – Contracted Research What is the immune system? A network of proteins, cells, tissues and organs all coordinated for one purpose: to defend one organism from another It is an infinitely adaptable system to combat the complex and endless variety of pathogens it must address Outline Structure of the immune system Anatomy of an immune response Role of the immune system in disease: infection, cancer and autoimmunity Organs of the Immune System Major organs of the immune system 1. Bone marrow – production of immune cells 2. Thymus – education of immune cells 3. Lymph Nodes – where an immune response is produced 4. Spleen – dual role for immune responses (especially antibody production) and cell recycling Origins of the Immune System B-Cell B-Cell Self-Renewing Common Progenitor Natural Killer Lymphoid Cell Progenitor Thymic T-Cell Selection Hematopoetic T-Cell Stem Cell Progenitor Dendritic Cell Myeloid Progenitor Granulocyte/M Macrophage onocyte Progenitor The Immune Response: The Art of War “Know your enemy and know yourself and you can fight a hundred battles without disaster.” -Sun Tzu, The Art of War Immunity: Two Systems and Their Key Players Adaptive Immunity Innate Immunity Dendritic cells (DC) B cells Phagocytes (Macrophages, Neutrophils) Natural Killer (NK) Cells T cells Dendritic Cells: “Commanders-in-Chief” • Function: Serve as the gateway between the innate and adaptive immune systems.
    [Show full text]
  • Human Anatomy As Related to Tumor Formation Book Four
    SEER Program Self Instructional Manual for Cancer Registrars Human Anatomy as Related to Tumor Formation Book Four Second Edition U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutesof Health SEER PROGRAM SELF-INSTRUCTIONAL MANUAL FOR CANCER REGISTRARS Book 4 - Human Anatomy as Related to Tumor Formation Second Edition Prepared by: SEER Program Cancer Statistics Branch National Cancer Institute Editor in Chief: Evelyn M. Shambaugh, M.A., CTR Cancer Statistics Branch National Cancer Institute Assisted by Self-Instructional Manual Committee: Dr. Robert F. Ryan, Emeritus Professor of Surgery Tulane University School of Medicine New Orleans, Louisiana Mildred A. Weiss Los Angeles, California Mary A. Kruse Bethesda, Maryland Jean Cicero, ART, CTR Health Data Systems Professional Services Riverdale, Maryland Pat Kenny Medical Illustrator for Division of Research Services National Institutes of Health CONTENTS BOOK 4: HUMAN ANATOMY AS RELATED TO TUMOR FORMATION Page Section A--Objectives and Content of Book 4 ............................... 1 Section B--Terms Used to Indicate Body Location and Position .................. 5 Section C--The Integumentary System ..................................... 19 Section D--The Lymphatic System ....................................... 51 Section E--The Cardiovascular System ..................................... 97 Section F--The Respiratory System ....................................... 129 Section G--The Digestive System ......................................... 163 Section
    [Show full text]
  • M. H. RATZLAFF: the Superficial Lymphatic System of the Cat 151
    M. H. RATZLAFF: The Superficial Lymphatic System of the Cat 151 Summary Four examples of severe chylous lymph effusions into serous cavities are reported. In each case there was an associated lymphocytopenia. This resembled and confirmed the findings noted in experimental lymph drainage from cannulated thoracic ducts in which the subject invariably devdops lymphocytopenia as the lymph is permitted to drain. Each of these patients had com­ munications between the lymph structures and the serous cavities. In two instances actual leakage of the lymphography contrrult material was demonstrated. The performance of repeated thoracenteses and paracenteses in the presenc~ of communications between the lymph structures and serous cavities added to the effect of converting the. situation to one similar to thoracic duct drainage .The progressive immaturity of the lymphocytes which was noted in two patients lead to the problem of differentiating them from malignant cells. The explanation lay in the known progressive immaturity of lymphocytes which appear when lymph drainage persists. Thankful acknowledgement is made for permission to study patients from the services of Drs. H. J. Carroll, ]. Croco, and H. Sporn. The graphs were prepared in the Department of Medical Illustration and Photography, Dowristate Medical Center, Mr. Saturnino Viloapaz, illustrator. References I Beebe, D. S., C. A. Hubay, L. Persky: Thoracic duct 4 Iverson, ]. G.: Phytohemagglutinin rcspon•e of re­ urctcral shunt: A method for dccrcasingi circulating circulating and nonrecirculating rat lymphocytes. Exp. lymphocytes. Surg. Forum 18 (1967), 541-543 Cell Res. 56 (1969), 219-223 2 Gesner, B. M., J. L. Gowans: The output of lympho­ 5 Tilney, N.
    [Show full text]
  • | Tidsskrift for Den Norske Legeforening a Previously Healthy Man in His Late Forties Consulted His Doctor About a Lump in His Anus
    A man in his forties with anal tumour and inguinal lymphadenopathy NOE Å LÆRE AV SVETLANA SHARAPOVA E-mail: [email protected] Department of Gastrointestinal and Paediatric Surgery Oslo University Hospital Svetlana Sharapova, specialty registrar in general surgery and gastrointestinal surgery, and acting consultant. The author has completed the ICMJE form and declares no conflicts of interest. USHA HARTGILL Olafia Clinic Department of Venereology Oslo University Hospital Usha Hartgill, specialist in dermatological and venereal diseases, head of department and senior consultant. The author has completed the ICMJE form and declares no conflicts of interest. PREMNAATH TORAYRAJU Olafia Clinic Department of Venereology Oslo University Hospital Premnaath Torayraju, specialty registrar in the Department of Medicine at Diakonhjemmet Hospital, specialising in dermatological and venereal diseases. The author has completed the ICMJE form and declares no conflicts of interest. BETTINA ANDREA HANEKAMP Department of Radiology Oslo University Hospital Bettina Andrea Hanekamp, specialist in radiology, and senior consultant in the Section for Oncological and Abdominal Imaging. The author has completed the ICMJE form and declares no conflicts of interest. SIGURD FOLKVORD Department of Gastrointestinal and Paediatric Surgery Oslo University Hospital Sigurd Folkvord, PhD, senior consultant and specialist in gastrointestinal surgery. The author has completed the ICMJE form and declares no conflicts of interest. A man in his late forties was examined for suspected cancer of the anal canal with spreading to inguinal lymph nodes. When biopsies failed to confirm malignant disease, other differential diagnoses had to be considered. A man in his forties with anal tumour and inguinal lymphadenopathy | Tidsskrift for Den norske legeforening A previously healthy man in his late forties consulted his doctor about a lump in his anus.
    [Show full text]
  • Case 3.1 X-Linked Agammaglobulinaemia (Bruton’S Disease)
    Case 3.1 X-linked agammaglobulinaemia (Bruton’s disease) Peter was born after an uneventful pregnancy, weighing 3.1 kg. At 3 months, he developed otitis media; at the ages of 5 months and 11 months, he was admitted to hospital with untypable Haemophilus influenzae pneumonia. These infections responded promptly to appropriate antibiotics on each occasion. He is the fourth child of unrelated parents: his three sisters showed no predisposition to infection. Examination at the age of 18 months showed a pale, thin child whose height and weight were below the third centile. There were no other abnormal features. He had been fully immunized as an infant (at 2, 3 and 4 months) with tetanus and diphtheria toxoids, acellular pertussis, Hib and Mening. C conjugate vaccines and polio (Salk). In addition, he had received measles, mumps and rubella vaccine at 15 months. All immunizations were uneventful. Immunological investigations (Table 3.4) into the cause of his recurrent infections showed severe reduction in all three classes of serum immunoglobulins and no specific antibody production. Although there was no family history of agammaglobulinaemia, the lack of mature B lymphocytes in his peripheral blood suggested a failure of B-cell differentiation and strongly supported a diagnosis of infantile X-linked agammaglobulinaemia (Bruton’s disease). This was confirmed by detection of a disease-causing mutation in the Btk gene. The antibody deficiency was treated by 2-weekly intravenous infusions of human normal IgG in a dose of 400 mg/kg body weight/month. Over the following 7 years, his health steadily improved, weight and height are now on the 30th centile, and he has had only one episode of otitis media in the last 4 years.
    [Show full text]
  • Association of GUTB and Tubercular Inguinal Lymphadenopathy - a Rare Co-Occurrence
    IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-ISSN: 2279-0853, p-ISSN: 2279-0861.Volume 15, Issue 7 Ver. I (July 2016), PP 109-111 www.iosrjournals.org Association of GUTB and Tubercular inguinal lymphadenopathy - A rare co-occurrence. 1Hemant Kamal, 2Dr. Kirti Kshetrapal, 3Dr. Hans Raj Ranga 1Professor, Department of Urology & reconstructive surgery, PGIMS Rohtak-124001 (Haryana) Mobile- 9215650614 2Prof. Anaesthesia PGIMS Rohtak, 3Associate Prof. Surgery PGIMS Rohtak. Abstract : Here we present a rare combination of GUTB with B/L inguinal lymphadenopathy in a 55y old male patient presented with pain right flank , fever & significant weight loss for the last 3 months. Per abdomen examination revealed non-tender vague lump in right lumber region about 5x4cm dimensions , with B/L inguinal lymphadenopathy, firm, matted . Investigations revealed low haemoglobin count, high leucocytic & ESR count , urine for AFB was positive and ultrasound revealed small right renal & psoas abscess , which on subsequent start of ATT , got resolved and patient was symptomatically improved . I. Introduction Genitourinary tuberculosis (GUTB) is the second most common form of extrapulmonary tuberculosis after lymph node involvement [1]. Most studies in peripheral LNTB have described a female preponderance, while pulmonary TB is more common in adult males [2]. In approximately 28% of patients with GUTB, the involvement is solely genital [3]. However , the combination of GUTB and LNTB is rare condition. Most textbooks mention it only briefly. This report aims to present a case of GUTB with LNTB in a single patient. II. Case Report 55y male with no comorbidities , having pain right flank & fever X 3months.
    [Show full text]
  • The Size of Lymph Nodes in the Neck on Sonograms As a Radiologic Criterion for Metastasis: How Reliable Is It?
    AJNR Am J Neuroradiol 19:695–700, April 1998 The Size of Lymph Nodes in the Neck on Sonograms as a Radiologic Criterion for Metastasis: How Reliable Is It? Michiel W. M. van den Brekel, Jonas A. Castelijns, and Gordon B. Snow PURPOSE: A definition of cut-off points for nodal size is essential to determine whether cervical lymph nodes are metastatic or not. Because the currently used size criteria are defined for random populations of patients with head and neck cancer, we set out to study whether these criteria are optimal for patients without palpable metastases in different levels of the neck. We defined optimal size criteria for sonography by calculating the sensitivity and specificity of different size cut-off points. METHODS: We compared the sensitivity and specificity of different size cut-off points as measured on sonograms for various levels in the neck in a series of 117 patients with and 131 patients without palpable neck metastases. RESULTS: A minimum axial diameter of 7 mm for level II and 6 mm for the rest of the neck revealed the optimal compromise between sensitivity and specificity in necks without palpable metastases. For all necks together (with and without palpable metastases), the criteria were 1 to 2 mm larger. CONCLUSION: Our findings indicate that the current sonographic size criteria used for random patient populations are not optimal for necks without palpable metastases, nor can the same cut-off points be used for all levels in the neck. The management of lymph node metastases in the cious lymph nodes may convert both selective neck neck in patients with squamous cell carcinoma of the treatment and a wait-and-see policy to more secure upper air and food passages is a continuing source of comprehensive treatment of all levels of the neck (6).
    [Show full text]
  • Brain-To-Cervical Lymph Node Signaling After Stroke
    ARTICLE https://doi.org/10.1038/s41467-019-13324-w OPEN Brain-to-cervical lymph node signaling after stroke Elga Esposito1, Bum Ju Ahn1, Jingfei Shi1,2, Yoshihiko Nakamura 1,3, Ji Hyun Park1, Emiri T. Mandeville 1, Zhanyang Yu1, Su Jing Chan 1,4, Rakhi Desai1, Ayumi Hayakawa1, Xunming Ji2, Eng H. Lo1,5*& Kazuhide Hayakawa1,5* After stroke, peripheral immune cells are activated and these systemic responses may amplify brain damage, but how the injured brain sends out signals to trigger systemic inflammation remains unclear. Here we show that a brain-to-cervical lymph node (CLN) 1234567890():,; pathway is involved. In rats subjected to focal cerebral ischemia, lymphatic endothelial cells proliferate and macrophages are rapidly activated in CLNs within 24 h, in part via VEGF-C/ VEGFR3 signalling. Microarray analyses of isolated lymphatic endothelium from CLNs of ischemic mice confirm the activation of transmembrane tyrosine kinase pathways. Blockade of VEGFR3 reduces lymphatic endothelial activation, decreases pro-inflammatory macro- phages, and reduces brain infarction. In vitro, VEGF-C/VEGFR3 signalling in lymphatic endothelial cells enhances inflammatory responses in co-cultured macrophages. Lastly, surgical removal of CLNs in mice significantly reduces infarction after focal cerebral ischemia. These findings suggest that modulating the brain-to-CLN pathway may offer therapeutic opportunities to ameliorate systemic inflammation and brain injury after stroke. 1 Neuroprotection Research Laboratory, Departments of Radiology and Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA. 2 China-America Institute of Neuroscience, Xuanwu Hospital, Capital Medical University, Beijing, China. 3 Department of Emergency and Critical Care Medicine, Fukuoka University Hospital, Jonan, Fukuoka, Japan.
    [Show full text]